TEMPE, Ariz., Aug. 2, 2007 (PRIME NEWSWIRE) -- OrthoLogic Corp. (Nasdaq:OLGC) today announced the formation of a Scientific Advisory Board (SAB) with the appointments of Michael E. Mendelsohn, M.D. of Tufts-New England Medical Center and Charles A. Dinarello, M.D. of University of Colorado School of Medicine. The SAB will provide independent scientific advice and counsel to OrthoLogic Management and Board of Directors regarding key development decisions for the Company's novel synthetic peptides Chrysalin(r) (TP508) and AZX100. Dr. Mendelsohn will serve as Chairman of the SAB.
